Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial
John Mascarenhas(Tisch Hospital), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Rupali Bhave(Atrium Health Wake Forest Baptist), Lilian Varricchio(Icahn School of Medicine at Mount Sinai), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Aaron T. Gerds(Cleveland Clinic), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Andrew Kuykendall(Moffitt Cancer Center), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Jeanne Palmer(Mayo Clinic), Anna Ritá Migliaccio(Altius Institute for Biomedical Sciences), Amelia Gabler(Johns Hopkins University), Amylou C. Dueck(Mayo Clinic in Arizona), Maureen D. O'Connor‐McCourt(Micropharma (Canada)), Paul I. Nadler, Gilles Tremblay, Rami S. Komrokji(Moffitt Cancer Center)
Cited by 11
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k